Pfizer and Valneva plan to seek approval for their Lyme disease vaccine, reporting 'clinically meaningful' efficacy despite not meeting the primary study objective due to a lower-than-expected infection rate. This move highlights their commitment to addressing Lyme disease amidst mixed trial results.
The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.
Original title: “Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results”